Skip to main content
20th International Myeloma Workshop Main banner
Back

    Rafael Fonseca, MD

    Chief Innovation Officer
    Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA
    Phoenix, Arizona, United States

    Rafael Fonseca, MD, is the Getz Family Professor of Cancer, Professor of Medicine, Chief Innovation Officer, a consultant in the Division of Hematology/Oncology at the Mayo Clinic in Arizona and a member of the Mayo Clinic Board of Governors and Board of Trustees. He earned his MD at Universidad Anahuac, Mexico. He completed a residency in internal medicine at the University of Miami, FL, and a fellowship in hematology and medical oncology at Mayo Graduate School of Medicine, Rochester, MN. He was named a clinical investigator for the Damon Runyon Cancer Research Fund. He is a visiting healthcare fellow at the Goldwater Institute.

    Dr Fonseca’s practice has focused on the diagnosis and treatment of plasma cell disorders and leading the multiple myeloma team in its efforts to develop a better understanding of the disease and its impact on patients. In his laboratory, Dr Fonseca has led his team of researchers regarding the genetic nature of clonal cells of plasma cell disorders, myeloma bone disease, prognostic markers, and development of new therapies for the disease. He is an active participant and leader of myeloma clinical trials.

    Throughout his training and career, Dr Fonseca has received numerous awards and honors, including the Damon Runyon-Walter Winchell Clinical Investigator Award, and the International Waldenström Macroglobulinemia Research Award. Most notably, he is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at his institution. Dr Fonseca holds memberships and serves in positions for organizations such as the American Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, and the International Myeloma Society. His research has been funded by the National Cancer Institute (R01, P01, SPORE), the Leukemia & Lymphoma Society, the Multiple Myeloma Research Fund, and the Damon Runyon Cancer Research Fund.

    Presentation(s):